Effectiveness of Early Remdesivir Initiation in Patients with Immunocompromising Conditions Hospitalized with COVID-19 by Variant Era, Level of Immunocompromise, and Age.

Immunocompromised patients with COVID-19 face higher risks of progression and mortality, but the real-world effectiveness of early remdesivir initiation in this vulnerable subgroup had not been estimated using causal methods.

Target RWE researchers applied rigorous causal methods to estimate the effectiveness of early remdesivir initiation in immunocompromised patients hospitalized with COVID-19, addressing time-varying confounding using the clone-censor-weight framework.

Demonstrating real-world effectiveness of early remdesivir in immunocompromised COVID-19 patients provides Gilead with targeted post-authorization evidence for this high-priority subgroup.

Early remdesivir effectiveness evidence in immunocompromised COVID-19 patients for Gilead post-authorization label strategy, Clone-censor-weight application for dynamic treatment protocol effectiveness in vulnerable COVID-19 populations